FDA Drug Safety Oversight Could Be “Transformed” By Medicare Data
Executive Summary
FDA should develop an active surveillance system using prescription drug claims data from the Medicare population to supplement its existing drug safety system, members of the agency's Drug Safety & Risk Management Advisory Committee said May 18 and 19
You may also be interested in...
Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot
An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva
Atrovent, Spiriva Safety To Be Tracked In Pharmacy Active Surveillance Pilot
An active drug surveillance system pilot, directed by the Critical Path Institute (C-Path), will track safety and efficacy information for the chronic obstructive pulmonary disorder therapies Atrovent and Spiriva
FDA/CDC Active Surveillance System Could Assess Effect Of Safety Measures
A collaborative national electronic active surveillance system co-sponsored by FDA and the Centers for Disease Control & Prevention could be used to examine the impact of safety measures on the number of adverse drug events, CDC medical officer Dan Budnitz said July 7